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While all pestiviruses share the same genomic structure, heterogeneity is also a feature that is also 
common among all pestiviruses. This diversity in bovine pestiviruses can be observed in nucleotide 
sequences, antigenic properties, infections in difference host species, virulence, biotype, and different 
types of infections that include persistent and acute. Given the complexity of pestiviruses and the 
interactions with their hosts, it may seem difficult to find similar characteristics shared among bovine 
pestiviruses without over simplifying these interactions. While bovine pestiviruses share common 
aspects, it is still imperative to understand the uniqueness of each respective isolate and the spectrum 
that can still exist within each of the characteristics. For the purpose of this discussion, the 
characteristics that are shared among all pestiviruses to be further explored include; replication in 
immune tissues that leads to changes in immune cells and tissues, resulting in immunomodulation; the 
ability to cross the placenta; and antigenic cross-reactivity.  
 
Previous research has described lymphopenia and thymic depletion associated with bovine viral 
diarrhea virus (BVDV) infections [6-8].  Further, it was determined that the degree of depletion was 
associated with the virulence of the virus [2]. The T cell population is of particular interest as the 
greatest decline is observed in the CD4+ T-lymphocytes in the periphery, but this population returns to 
baseline values by day 14 after challenge with typical virulent BVDV isolates [2]. Additionally, significant 
depletion of the thymus is observed, which is the maturation site of T cells. Collectively this data causes 
concern as it relates to the long-term impact on the developing immune system as T cells contribute to 
cell mediated immunity and protective responses. 
 
Modified-live vaccines are of particular interest, as only one killed vaccine has a fetal protection claim 
and previous research would suggest MLV vaccines confer greater fetal protection [15, 16]. While MLV 
vaccines may confer greater protection, this increased protection may come at a cost. As new vaccines 
are developed, an understanding of the impact vaccination has on the developing bovine immune 
system will be necessary to better compare the potential advantages and disadvantages of different 
vaccination strategies.  
 
Furthermore, current licensed vaccines in the US only contain BVDV-1a and BVDV-2a strains [4], but the 
most recent surveillance would suggest that BVDV-1b strains are the most prevalent in the US [10-11]. 
This increased prevalence in BVDV1b isolates has been associated with lack of protection conferred by 
the current licensed vaccines. Protective responses associated with conferring fetal protection against 
BVDV involves several aspects of the immune response. Serum-neutralizing antibodies are an important 
component of the immune response. This is the most commonly used method, and considered the gold 
standard to evaluate protective responses against BVDV isolates that are genetically and antigenically 
diverse [1, 9]. While virus neutralization titers (VNT) are correlated with increased protection against 
BVDV [10, 15], other components of the immune response that may contribute to protection include 
mucosal immunity; cytotoxic T cells, which can kill virus infect cells; and T-helper-1 cells, which secrete 
IFN-γ and has anti-viral properties [11].  
 
Other components of the immune response need to be considered and evaluated when describing 
protective responses. Serum virus-neutralizing antibodies may be sufficient to protect healthy non-
stressed animals during an acute infection with BVDV, but conferring fetal protection may require a 
greater level of protection by effectively stimulating all aspects of acquired immunity [5], which needs to 
be measured in combination with neutralizing titers.  
 
Previous research has highlighted the importance of cell associated BVDV by; demonstrating cows that 
give birth to PI animals have prolonged or increased viremia; the degree of viremia induced during BVDV 
infection is associated with clinical disease as defined by increased number of day of pyrexia and 
decrease in circulating lymphocytes; and PI calf health outcomes are associated with the frequency of 
BVDV positive PBMC populations [4, 14, 16]. Collectively, this research suggests that the frequency or 
amount of BVDV positive cells is an important indicator of clinical outcomes associated with BVDV 
infections and should be considered for immunological assays, but reliable and consistent methods for 
intracellular staining of BVDV by flow cytometry have been problematic [12, 13]. Only recently a new 
flow cytometry method was developed that reliably and reproducibly detects and quantifies the number 
of BVDV positive cells within respective cell populations at the single cell level [3, 4]. This new method of 
BVDV intracellular detection has been further expanded to evaluate competition between multiple 
BVDV isolates, as well as incorporate cell responses previously reported to be associated with CMI. 
Development of these new assays allows for a more comprehensive evaluation of protective responses 
as well as inherent difference that may exist between bovine pestiviruses.  
 
Considering the collective immunological and serological data associated with both BVDV acute and 
persistent infections, significant evidence suggest that the T cell population plays a critical role in the 
outcome of BVDV infections. For this reason, this population of cells has been evaluated as it relates 
replication in immune tissues and lymphoid depletion; antigen specific responses in correlation with 
serological response, and it’s collective role in protective responses against fetal infections.  
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